GET THE APP

Factor V Leiden Thrombophilia
Journal of Thrombosis and Circulation: Open Access

Journal of Thrombosis and Circulation: Open Access
Open Access

ISSN: 2572-9462

+44 7460731551

Mini Review - (2021) Volume 7, Issue 3

Factor V Leiden Thrombophilia

Ellen Joseph*
 
*Correspondence: Ellen Joseph, Department of Hematology, Columbia University, United States, ,

Author info »

Introduction

Factor V Leiden thrombophilia is portrayed by a helpless anticoagulant reaction to actuated protein C (APC) and an expanded danger for venous thromboembolism (VTE). Profound vein apoplexy (DVT) is the most widely recognized VTE, with the legs being the most well-known site. Apoplexy in strange areas is more uncommon. Proof proposes that heterozygosity for the Leiden variation has all things considered an unobtrusive impact on hazard for intermittent apoplexy after introductory treatment of a first VTE. It is impossible that factor V Leiden thrombophilia (i.e., heterozygosity or homozygosity for the Leiden variation) is a main consideration adding to pregnancy misfortune and other antagonistic pregnancy results (toxemia, fetal development limitation, and placental abruption).Factor V Leiden thrombophilia is associated in people with a set of experiences with venous thromboembolism (VTE) show as profound vein apoplexy (DVT) or aspiratory embolism, particularly in ladies with a background marked by VTE during pregnancy or in relationship with utilization of estrogen-containing contraceptives, and in people with an individual or family background of intermittent apoplexy. The determination of factor V Leiden thrombophilia is set up in a proband by distinguishing proof of heterozygous and homozygous in a combination with coagulation tests, for example, the APC obstruction test [1].

The main intense apoplexy is treated by standard rules. The term of oral anticoagulation treatment ought to be founded on an appraisal of the dangers for VTE repeat and anticoagulantrelated dying.

Anticipation of essential signs: without a background marked by apoplexy, long haul prophylactic anticoagulation isn't regularly suggested for asymptomatic Leiden variation heterozygotes. A short course of prophylactic anticoagulation when fortuitous danger factors are available may forestall beginning apoplexy in Leiden variation heterozygotes [2].

Assessment of family members in danger: Although the hereditary status of obviously asymptomatic in danger relatives can be set up utilizing atomic hereditary testing, the signs for testing of in danger relatives are uncertain. Without proof that early ID of the Leiden variation prompts mediations that can lessen grimness or mortality, choices in regards to testing ought to be made on an individual premise. Be that as it may, if the outcomes are probably going to influence the executives, explanation of Leiden variation status might be shown in danger female family members thinking about hormonal contraception or pregnancy or in families with a solid history of repetitive venous apoplexy at a youthful age.Once the Leiden variation has been recognized in a relative, pre-birth testing for pregnancies at expanded danger and preimplantation hereditary testing are conceivable .[3]

Conclusion

Without a background marked by apoplexy, long haul anticoagulation isn't regularly suggested for asymptomatic people who are heterozygous for the Leiden variation in light of the fact that the 1%-3%/year hazard for significant seeping from warfarin is more noteworthy than the assessed under 1%/year hazard for apoplexy.

References

1. Rosing J, Tans G. Coagulation factor V: an old star shines again. Thrombosis and Haemostasis. 1997;78(1):427–433.
2. Butenas S, Mann KG. Blood coagulation. Biochemistry. 2002;67(1):3–12.
3. Hooper WC, de Staercke C. The relationship between FV Leiden and pulmonary embolism. Respiratory Research. 2002;3:p. 8

 

Author Info

Ellen Joseph*
 
Department of Hematology, Columbia University, United States
 

Citation: Joseph E (2021) Factor V Leiden Thrombophilia J Thrombo Cir. 7:156. 10.35248/2572-9462-7.156.

Received Date: May 05, 2021 / Accepted Date: May 24, 2021 / Published Date: May 31, 2021

Copyright: ©2021 Joseph E. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Top